-
HRP Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-08-27
HRP Goat Anti-Mouse IgG (H+L) Antibody, SKU K1221, provides an HRP-labeled secondary reagent for detecting mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It should not be treated as a universal secondary antibody or used without optimization for non-mouse primary antibodies, mouse tissues, or assays requiring fluorescence.
-
Sodium Oxamate: Mapping Lactate-Linked Signaling
2026-08-27
Sodium Oxamate is more than an LDH-A inhibitor: it can help separate glycolytic flux from lactate-dependent signaling. This article develops a cross-domain assay framework linking cancer metabolism research with emerging evidence on BVDV immune evasion while clearly defining experimental limits.
-
Glycogen Colorimetric Assay Kit II for Metabolic Studies
2026-08-26
The Glycogen Colorimetric Assay Kit II converts glycogen to a measurable glucose-derived color signal, supporting sensitive analysis in tissue, disease, exercise, and circadian studies. Its interference-aware design and plate-compatible workflow are especially useful when reducing substances complicate conventional oxidase-based measurements.
-
Abiraterone Acetate in 3D Prostate Cancer Models
2026-08-26
Learn how to deploy Abiraterone acetate as a CYP17 inhibitor in two-dimensional assays and patient-derived prostate cancer spheroids. This workflow emphasizes model selection, solvent control, androgen receptor activity inhibition, comparative drug testing, and troubleshooting when three-dimensional cultures show limited response.
-
Cell Lysis Buffer for WB and IP in CAF Research
2026-08-25
Cell lysis buffer for WB and IP can help preserve phosphorylation states and native protein associations when dissecting CAF-driven chemoresistance. This guide maps lysis chemistry to ANGPTL4-IQGAP1 pathway assays, controls, and interpretation limits.
-
Dextrose (D-glucose) in Metabolism Research
2026-08-25
Dextrose, or D-glucose, is a defined monosaccharide substrate for glucose metabolism research, cell culture media supplementation, and cellular energy production studies. Its value in hypoxia and immunometabolism experiments is greatest when concentration, solvent, storage, and biological context are controlled separately.
-
Hypoxia-Activated BNNC Targets Cyclin K in Cancer
2026-08-24
The reference study introduces BNNC, a hypoxia-activated photomolecular glue designed to release the Cyclin K degrader (R)-CR8 together with the phototherapeutic agent BSS-Et in tumors. Cell and animal results indicate that coordinated Cyclin K degradation, DNA damage, and phototherapy can improve antitumor activity while preserving tumor-selective design logic.
-
FK866 (APO866): Mapping NAMPT Dependence Beyond AML
2026-08-24
FK866 (APO866) offers a precise way to interrogate NAMPT dependence, NAD depletion, mitochondrial stress, and selective vulnerability in hematologic cancer models. This thought-leadership analysis connects AML research with emerging evidence that NAMPT also governs DNA-damage responses and cellular aging, while defining the experimental controls needed for credible translation.
-
Necrostatin-1: RIP1 Kinase Workflow Guide
2026-08-23
Build cleaner necroptosis assays with Necrostatin-1, from TNF-α challenge experiments to virus–host and tissue-injury models. This guide connects RIP1 kinase inhibition with RIPK3/MLKL validation and practical troubleshooting for cell and acute kidney injury (AKI) research.
-
Se-Methylselenocysteine, NRF2–ATF4, and PDAC Ferroptosis
2026-08-22
This study shows that Se-methylselenocysteine (MSC) does not produce a uniform redox response in pancreatic ductal adenocarcinoma (PDAC). Instead, KYAT1-dependent metabolic activation determines whether cells engage NRF2-centered antioxidant programs, co-activate ATF4 and unfolded protein response signaling, or remain relatively resistant, linking stress adaptation to ferroptosis-associated remodeling.
-
Necrostatin-1: From RIP1 Inhibition to Translation
2026-08-22
Necrostatin-1 is more than a pathway probe: it is a strategic tool for testing whether RIP1-dependent necroptosis drives inflammation, infection, and organ injury. This article connects RIP1 kinase biology with host–pathogen evidence, assay design, competitive positioning, and translational decision-making.
-
Brefeldin A Workflows for ER–Golgi Studies
2026-08-21
Brefeldin A provides a practical way to perturb ER–Golgi trafficking, induce ER stress, and connect secretion defects with apoptosis or migration phenotypes. This workflow-focused guide shows how to dose BFA, build controls, interpret endothelial biomarker experiments, and troubleshoot common assay failures.
-
Canagliflozin Hemihydrate in Metabolic Assays
2026-08-20
Canagliflozin hemihydrate provides a practical chemical probe for studying SGLT2-linked glucose handling, renal glucose reabsorption, and metabolic pathway selectivity. Its negative result in a drug-sensitized yeast TOR screen also makes it useful as a boundary-setting control when researchers compare glucose transport biology with mTOR-dependent growth phenotypes.
-
Glucagon–GLP-1R Crosstalk in FRET cAMP Assays
2026-08-20
Chepurny and colleagues showed that glucagon can activate the GLP-1 receptor in addition to its canonical glucagon receptor, challenging assumptions about ligand selectivity. By combining high-throughput cAMP FRET assays, receptor-selective pharmacology, cell validation, and molecular modeling, the study clarified how antagonist controls can reveal promiscuous GPCR signaling and inform multi-receptor peptide design.
-
Prednisolone Workflows for Glucocorticoid Research
2026-08-19
Build reproducible Prednisolone workflows for glucocorticoid signaling research, inflammation modulation, and immunology assays. A carefully bounded comparison with ERAD-hijacking research shows how to use Prednisolone as a mechanistic context control without misidentifying it as a validated protein-degradation warhead.